Biopharma & Life Sciences

Harmony Biosciences Holdings Executive Compensation (FY25)

Name: Harmony Biosciences Holdings (HRMY) executive compensation
Creator: Velarion
License: https://intel.velarion.ai/terms

HRMY · Executive and director compensation, fiscal 2022 to 2025

Chief executive, fiscal 2025

◇

Jeffrey Dayno

Median of the other named officers

$2,346,945

5 officers, excluding the chief executive

Latest say-on-pay support

May 14, 2026

Chief executive pay ratio

◇

To the median employee

Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.

See every company’s exec pay — free for 3 days, no card See the plan and pricing

The Harmony Biosciences Holdings brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $500 for the board report; $900 for both.

Get the executive brief Get the board briefNo account needed.

Data as of November 5, 2026Latest filing: October 30, 2026

8 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Harmony Biosciences Holdings brief$500Get the executive brief

Velarion Intel, one year, every company

287 figures on this page: 285 cited to the filing that reported them, 2 calculated from figures it prints. See the citations

What changed from fiscal 2024 to fiscal 2025

The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.

Chief executive total compensation — Jeffrey Dayno: $7,145,170 → $7,899,535 (10.6% higher)

CEO pay ratio: 29:1 → 26:1 (10.3% lower)

Frequently asked questions

Answers drawn from the data on this page.

Who is Harmony Biosciences Holdings' chief executive and what were they paid?

Jeffrey Dayno, President and Chief Executive Officer, received $7,899,535 in total compensation for fiscal 2025. Compared with the $7,145,170 reported for fiscal 2024, Dayno's total was 10.6% higher.

What was Harmony Biosciences Holdings' say-on-pay result?

For fiscal 2025, shareholders backed the say-on-pay proposal with 71.8% of votes cast for or against in favor at the meeting held May 14, 2026.

Which companies are in Harmony Biosciences Holdings' peer group?

Companies named in the disclosed peer group include Acadia, Alkermes, Axsome, Intra-Cellular and Ionis, among others.

What is Harmony Biosciences Holdings' chief executive pay ratio?

The disclosed chief executive pay ratio for fiscal 2025 is 26:1, against median employee compensation of $303,481.

Executive compensation

Every element reported for each named executive officer, by fiscal year.

Fiscal 2022

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Sandip Kapadia Executive Vice President, Chief Financial Officer and Chief Administrative Officer	◇	◇	—	—	◇	—	◇	◇
Jeffrey Dayno President and Chief Executive Officer	◇	—	—	—	◇	—	◇	◇
Jeffrey Dierks Former Executive Vice President and Chief Commercial Officer	◇	—	—	—	◇	—	◇	◇
Andrew Serafin Executive Vice President and Chief Strategy Officer	◇	—	—	—	◇	—	◇	◇
John Jacobs Former President and Former Chief Executive Officer	◇	—	—	—	—	—	◇	◇

Fiscal 2023

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Jeffrey Dierks Former Executive Vice President and Chief Commercial Officer	◇	◇	◇	—	◇	—	◇	◇
Sandip Kapadia Executive Vice President, Chief Financial Officer and Chief Administrative Officer	◇	—	◇	—	◇	—	◇	◇
Jeffrey Dayno President and Chief Executive Officer	◇	◇	—	◇	◇	—	◇	◇
Kumar Budur Executive Vice President and Chief Medical and Scientific Officer	◇	◇	—	—	◇	—	◇	◇
Andrew Serafin Executive Vice President and Chief Strategy Officer	◇	—	—	—	◇	—	◇	◇
John Jacobs Former President and Former Chief Executive Officer Departed during or after this year	◇	—	—	—	—	—	◇	◇

Fiscal 2024

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Jeffrey Dayno President and Chief Executive Officer	◇	◇	◇	◇	◇	—	◇	◇
Kumar Budur EVP and Chief Medical & Scientific Officer	◇	—	◇	◇	◇	—	◇	◇
Sandip Kapadia EVP and Chief Financial Officer and Chief Administrative Officer	◇	◇	◇	◇	◇	—	◇	◇
Jeffrey Dierks EVP and Chief Commercial Officer	◇	◇	◇	◇	◇	—	◇	◇
Andrew Serafin EVP, Chief Strategy Officer	◇	◇	◇	◇	◇	—	◇	◇

Fiscal 2025

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Jeffrey Dayno President and Chief Executive Officer	◇	—	◇	◇	◇	—	◇	◇
Adam Zaeske Executive Vice President and Chief Commercial Officer	◇	◇	◇	◇	◇	—	◇	◇
Sandip Kapadia Executive Vice President, Chief Financial Officer and Chief Administrative Officer	◇	—	◇	◇	◇	—	◇	◇
Jeffrey Dierks Former Executive Vice President and Chief Commercial Officer Departed during or after this year	◇	—	◇	◇	—	—	◇	◇
Kumar Budur Executive Vice President and Chief Medical and Scientific Officer	◇	—	◇	◇	◇	—	◇	◇
Andrew Serafin Executive Vice President and Chief Strategy Officer	◇	—	◇	◇	◇	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.

Fiscal 2025

Officer	Award	Grant date	Threshold units	Target units	Units granted	Maximum units	Exercise price	Grant date fair value
Adam Zaeske	RSU	◇	—	—	◇	—	—	◇
Adam Zaeske	OPTION	◇	—	—	◇	—	◇	◇
Andrew Serafin	OPTION	◇	—	—	◇	—	◇	◇
Andrew Serafin	RSU	◇	—	—	◇	—	—	◇
Jeffrey Dierks	OPTION	◇	—	—	◇	—	◇	◇
Jeffrey Dierks	RSU	◇	—	—	◇	—	—	◇
Jeffrey M. Dayno	RSU	◇	—	—	◇	—	—	◇
Jeffrey M. Dayno	OPTION	◇	—	—	◇	—	◇	◇
Kumar Budur	RSU	◇	—	—	◇	—	—	◇
Kumar Budur	OPTION	◇	—	—	◇	—	◇	◇
Sandip Kapadia	RSU	◇	—	—	◇	—	—	◇
Sandip Kapadia	OPTION	◇	—	—	◇	—	◇	◇

Fiscal 2023, 2024 are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.

As disclosed at fiscal 2025 year end

Officer	Award	Unvested units	Market value of unvested units	Exercise price	Expires
Jeffrey Dayno	Option	◇	—	◇	1/25/35
	Option	◇	—	◇	1/24/34
	RSU	◇	◇	—	—
	Option	◇	—	◇	5/25/33
	RSU	◇	◇	—	—
Kumar Budur	Option	◇	—	◇	3/21/32
	RSU	◇	◇	—	—
	Option	◇	—	◇	5/1/34
	Option	◇	—	◇	1/25/35
	Option	◇	—	◇	1/24/34
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
Sandip Kapadia	Option	◇	—	◇	1/25/35
	RSU	◇	◇	—	—
	Option	◇	—	◇	1/24/34
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
Andrew Serafin	Option	◇	—	◇	1/25/35
	Option	◇	—	◇	1/24/34
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
Adam Zaeske	RSU	◇	◇	—	—

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.

Adam Zaeske

Executive Vice President and Chief Commercial Officer · Severance agreement

Severance multiple	◇
Severance base	◇
Severance cash amount	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Non-compete period	◇
Non-solicit period	◇

Andrew Serafin

Executive Vice President and Chief Strategy Officer · Terms as described in the company’s compensation discussion

Severance multiple	◇
Severance base	◇
Severance cash amount	◇
Change-in-control multiple	◇
Change-in-control base	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Non-compete period	◇
Non-solicit period	◇

Jeffrey Dayno

President and Chief Executive Officer · Severance agreement

Severance multiple	◇
Severance base	◇
Severance cash amount	◇
Equity acceleration on change in control	◇
Benefits continuation on change in control	◇
Benefits continuation	◇

Jeffrey Dierks

Former Executive Vice President and Chief Commercial Officer · Severance agreement

Severance cash amount	◇
Non-compete period	◇
Non-solicit period	◇

Kumar Budur

Executive Vice President and Chief Medical and Scientific Officer · Terms as described in the company’s compensation discussion

Severance multiple	◇
Severance base	◇
Severance cash amount	◇
Change-in-control multiple	◇
Change-in-control base	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Non-compete period	◇
Non-solicit period	◇

Sandip Kapadia

Executive Vice President, Chief Financial Officer and Chief Administrative Officer · Severance agreement

Severance multiple	◇
Severance cash amount	◇
Benefits continuation	◇

Director compensation

What each non-employee director was paid.

Fiscal 2025

Director	Fees earned in cash	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Ron Philip	◇	—	◇	—	—	—	◇
Gary Sender	◇	—	◇	—	—	—	◇
Antonio Gracias	◇	—	◇	—	—	—	◇
R. Mark Graf	◇	—	◇	—	—	—	◇
Juan A. Sabater	◇	—	◇	—	—	—	◇
Peter Anastasiou	◇	—	◇	—	—	—	◇
Linda Szyper	◇	—	◇	—	—	—	◇
Jeffrey S. Aronin Board chair	◇	—	—	—	—	—	◇

Troy Ignelzi, Geno Germano, Andreas Wicki and Jeffrey M. Dayno served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.

Earlier years are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.

Board cash retainer	◇
Board equity retainer	◇
Total board retainer	◇
Board chair premium	◇
Audit committee chair	◇
Audit committee member	◇
Compensation committee chair	◇
Compensation committee member	◇
Nominating and governance chair	◇
Nominating and governance member	◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Fiscal 2025

Acadia AKR
Alkermes ALKS
Axsome AXSM
Intra-Cellular ITCI
Ionis IONS
Jazz Pharmaceuticals JAZZ
Neurocrine Biosciences NBIX
Sage Therapeutics SAGE
Supernus SUPN

Say-on-pay history

Shareholder support for the compensation program, by year.

Year	Meeting	Support	Votes for	Votes against	Abstentions
2025	May 14, 2026	=	◇	◇	◇
2022	May 25, 2023	=	◇	◇	◇

Chief executive pay ratio

As calculated and reported by the company.

Ratio

◇

Median employee compensation

◇

Chief executive total compensation

◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”

- Jeffrey Dayno (President and Chief Executive Officer), FY2025 total compensation $7,899,535 (base salary $743,600) [exec_comp, SEC accession 0001104659-26-039449, filed 2026-04-03]

See a complete sample report

What this page does not include

Everything above is a fact Harmony Biosciences Holdings disclosed, and it is free. Everything below is our analysis of those facts, and it is not.

Peer benchmarking

Where Harmony Biosciences Holdings sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.

Executive Compensation Report — $500

Written compensation analysis

A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.

Executive Compensation Report — $500

Board and governance analysis

Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.

Board Governance Report — $500

Realizable pay

What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.

Velarion Intelligence

Adviser switching and vote outcomes

Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.

Inquire about access

Multiple companies at once

Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.

Velarion Intelligence

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.

287 figures on this page: 285 cited to the filing that reported them, 2 calculated from figures it prints.

285 cited to the filing

2 calculated from the filing

Documents cited

Filing, filed October 30, 2026
8-K, filed May 14, 2026
0001104659-26-061237
Filing, filed April 14, 2026
DEF 14A, filed April 3, 2026
0001104659-26-039449
CEO Pay Ratio · Director Compensation · Director Compensation Table · Grants of Plan-Based Awards · and 2 more sections
Filing, filed April 3, 2026
DEF 14A, filed April 4, 2025
0001140361-25-012336
Executive Compensation Tables
DEF 14A, filed April 11, 2024
0001140361-24-019230
Executive Compensation Tables
8-K, filed May 26, 2023
0001558370-23-010532

Cite this data

This page is free to cite. Attribution we ask for:

Velarion, “Harmony Biosciences Holdings executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/HRMY (accessed 2026).

Short form: data: Velarion

The Harmony Biosciences Holdings brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

From $500 for the board report; $900 for both.

Get the executive brief Get the board briefNo account needed.

8 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Embed this data

A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.

The headline figures, each with its citation.

<iframe src="https://intel.velarion.ai/comp/HRMY/embed" width="560" height="480" style="border:1px solid #d8dee8;border-radius:10px" loading="lazy" title="Harmony Biosciences Holdings executive compensation, from Velarion"></iframe>

Connect an AI assistant

Ask your own assistant about Harmony Biosciences Holdings and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

{
  "mcpServers": {
    "velarion": {
      "type": "http",
      "url": "https://api.velarion.ai/mcp"
    }
  }
}

Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life Sciences CEO pay ratio — Biopharma & Life Sciences Say-on-pay support — Biopharma & Life Sciences

Peers Harmony Biosciences Holdings discloses

The companies named in HRMY's own disclosed peer group.

Acadia Alkermes Axsome Intra-Cellular Ionis Jazz Pharmaceuticals Neurocrine Biosciences Sage Therapeutics Supernus

Terms on this page

Say-on-Pay Vote CEO Pay Ratio Median Employee Compensation All companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data

APA

Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854

BibTeX

@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}